Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949388 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Innovation Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT02949388: Completed Phase 2 study, sponsored by Innovation Pharmaceuticals.
NCT02949388 is a Phase 2 study that has completed, run by Innovation Pharmaceuticals. The registered enrollment target is 199 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02949388, a Phase 2 study, has completed, sponsored by Innovation Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.
Primary Outcome
The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).
Interventions
- DRUG Placebo
- DRUG 400 mg (200 mg BID)
- DRUG 300 mg (150 mg BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
What the finished NCT02949388 record still lists
NCT02949388 is an interventional study that assigns participants to a tested intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02949388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02949388 about?
NCT02949388 is a clinical study titled "Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis". This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT02949388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2016-11. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02949388?
The interventions under investigation include: Placebo (DRUG), 400 mg (200 mg BID) (DRUG), 300 mg (150 mg BID) (DRUG).
Who is sponsoring clinical trial NCT02949388?
This trial is sponsored by Innovation Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02949388's enrollment target sits among peer trials
199 349th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia